Clinical profile of comorbidities in patients with severe asthma undergoing benralizumab biologic therapy
References
- Miron R, Dantes E, Mihaltan FD, et al. (2022). The burden of asthma in Romania: current data and public health priorities. Pneumologia, 71(2), 90–97. Bing, https://www.bing.com/search?q=Miron+R%2C+Dantes+E%2C+Mihaltan+FD%2C+et+al.+(2022).+The+burden+of+asthma+in+Romania%3A+current+data+and+public+health+priorities.+Pneumologia%2C+71(2)%2C+90–97.&PC=U316&FORM=CHROMN (accessed 14 July 2025).
- Bănărescu CF, Panaitescu C. Impactul clinic și managementul comorbidităţilor în astmul sever. Alergologia, https://www.medichub.ro/reviste-de-specialitate/alergologia/impactul-clinic-si-managementulcomorbiditatilor-in-astmul-sever-id-7167-cmsid-99 (2022, accessed 14 July 2025).
- Chipps BE, Newbold P, Hirsch I, et al. Benralizumab efficacy by atopy status and serum immunoglobulin E for patients with severe, uncontrolled asthma. Ann Allergy Asthma Immunol 2018; 120: 504-511.e4.
- Agache I, Akdis CA, Akdis M, et al. EAACI Biologicals Guidelines-Recommendations for severe asthma. Allergy 2021; 76: 14–44.
- Garcia-Clemente M, de la Rosa D, Máiz L, et al. Impact of Pseudomonas aeruginosa Infection on Patients with Chronic Inflammatory Airway Diseases. J Clin Med 2020; 9: 3800.
- Zhang S-Q, Xiong X-F, Wu Z-H, et al. Clinical features of asthma with comorbid bronchiectasis: A systematic review and meta-analysis. Medicine (Baltimore) 2021; 100: e23858.
- Cazzola M, Calzetta L, Bettoncelli G, et al. Asthma and comorbid medical illness. European Respiratory Journal 2011; 38: 42–49.
- Gershon AS, Wang C, Guan J, et al. Burden of comorbidity in individuals with asthma. Thorax 2010; 65: 612–618.
- Scioscia G, Tondo P, Nolasco S, et al. Benralizumab in Patients with Severe Eosinophilic Asthma: A Multicentre Real-Life Experience. Journal of Clinical Medicine 2023; 12: 4362.
- Breslavsky A, Al Qaied A, Tsenter P, et al. Comparison of clinical remission criteria for severe asthma patients receiving biologic therapy. Respir Med 2024; 222: 107528.
- Harrison TW, Chanez P, Menzella F, et al. Onset of effect and impact on health-related quality of life, exacerbation rate, lung function, and nasal polyposis symptoms for patients with severe eosinophilic asthma treated with benralizumab (ANDHI): a randomised, controlled, phase 3b trial. Lancet Respir Med 2021; 9: 260–274.
- Kavanagh JE, Hearn AP, Dhariwal J, et al. Real-World Effectiveness of Benralizumab in Severe Eosinophilic Asthma. Chest 2021; 159: 496–506.
- Padilla-Galo A, Moya Carmona I, Ausín P, et al. Achieving clinical outcomes with benralizumab in severe eosinophilic asthma patients in a real-world setting: orbe II study. Respir Res 2023; 24: 235.
- FitzGerald JM, Bleecker ER, Nair P, et al. Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial. The Lancet 2016; 388: 2128–2141.
- Reddel HK, FitzGerald JM, Bateman ED, et al. GINA 2019: a fundamental change in asthma management: Treatment of asthma with short-acting bronchodilators alone is no longer recommended for adults and adolescents. Eur Respir J 2019; 53: 1901046.
- 2024 GINA Main Report. Global Initiative for Asthma - GINA, https://ginasthma.org/2024-report/ (accessed 15 March 2025).
- Schleich F, Moermans C, Seidel L, et al. Benralizumab in severe eosinophilic asthma in real life: confirmed effectiveness and contrasted effect on sputum eosinophilia versus exhaled nitric oxide fraction – PROMISE. ERJ Open Res 2023; 9: 00383–02023.
- Shah PA, Brightling C. Biologics for severe asthma-Which, when and why? Respirology 2023; 28: 709–721.
- Francisco-Javier GONZÁLEZ-BARCALA | Clinical Consultant, Asthma Clinical Research ÇUnit | MD,PhD | Conselleria de Sanidade, Santiago de Compostela | SERGAS | Respiratory | Research profile. ResearchGate, https://www.researchgate.net/profile/Francisco-Javier-Gonzalez-Barcala (accessed 14 July 2025).
- Kavanagh JE, Hearn AP, Dhariwal J, et al. Real-World Effectiveness of Benralizumab in Severe Eosinophilic Asthma. Chest 2021; 159: 496–506.
- Bleecker ER, Wechsler ME, FitzGerald JM, et al. Baseline patient factors impact on the clinical efficacy of benralizumab for severe asthma. Eur Respir J 2018; 52: 1800936.
- Barroso B, Valverde-Monge M, Alobid I, et al. Improvement in Olfaction in Patients With CRSwNP and Severe Asthma Taking Anti-IgE and Anti-IL-5 Biologics: A Real-Life Study. J Investig Allergol Clin Immunol 2023; 33: 37–44.
Language: English
Page range: 19 - 23
Submitted on: Jul 24, 2025
Accepted on: Oct 16, 2025
Published on: Mar 10, 2026
In partnership with: Paradigm Publishing Services
Publication frequency: 4 issues per year
Related subjects:
© 2026 Corina Mărginean, Dragoș Huțanu, Mara Andreea Vultur, Hédi-Katalin Sárközi, Edith-Simona Ianoși, Maria Beatrice Ianoși, Andreea Safta, Gabriela Jimborean, Corina Eugenia Budin, published by University of Medicine, Pharmacy, Science and Technology of Targu Mures
This work is licensed under the Creative Commons Attribution 4.0 License.